EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. reports progress on regulatory fronts and corporate growth, including preclinical advances for its ExoPTEN drug and expansion of its financial footprint with an uplisting to the OTCQB Venture Market. The biopharmaceutical company also highlights a net loss increase in Q2 2024 compared to the same quarter in the previous year but reveals an improved cash position and working capital.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
